CDK4/6 Inhibitors for Metastatic Breast Cancer

Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors

Recruiting Observational Study
Anatomic Stage IV Breast Cancer AJCC v8 Metastatic Breast Carcinoma Prognostic Stage IV Breast Cancer AJCC v8
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
700 (estimated)
Sponsor
Roswell Park Cancer Institute · Other
Who this trial is looking for

This trial is looking for adult women with specific types of metastatic breast cancer who are being treated with certain therapies. Participants will provide samples to help understand the disease and treatment responses better.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am an adult patient.
  • I have been diagnosed with ER+/HER2- metastatic breast cancer.
  • I have been diagnosed with high risk early HR+/HER2-node positive breast cancer.
  • I am being treated with ciclib-based therapies.
  • I can understand the study and give my written consent.

You may not be able to join if

  • I am pregnant or nursing.
  • I am unwilling or unable to follow the study requirements.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial
This study investigates the clinical course of CDK4/6 inhibitor treated patients in the real-world setting among patients with breast cancer. CDK4/6 inhibitors may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Studying samples of blood, tissue, ascites or pleural effusions, and fresh body fluids or fresh biopsy, from patients with breast cancer that has spr…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * All adult patients with ER+/HER2- metastatic breast cancer or HR+/HER2-node positive, high risk early breast cancer who are being or have been treated with ciclib-based therapies are eligible for inclusion in this study * This includes patients receiving standard of care th…
Contacts

No contact information available.